Home > Pulmonology > ATS 2022 > Novel PDE4B inhibitor offers breakthrough for IPF

Novel PDE4B inhibitor offers breakthrough for IPF

Presented By
Prof. Luca Richeldi, Università Cattolica del Sacro Cuore, Italy
ATS 2022
Phase 2
Findings from a phase 2, randomised, placebo-controlled trial in patients with idiopathic pulmonary fibrosis (IPF) showed that the investigational drug BI 1015550, either alone or with background use of an anti-fibrotic agent, significantly prevented a decrease in lung function. The anti-inflammatory and immunomodulatory abilities of oral, selective phosphodiesterase 4B (PDE4B) inhibition has not yet been explored clinically for IPF. However, in a late-breaking session, Prof. Luca Richeldi (Università Cattolica del Sacro Cuore, Italy) presented the first clinical results of the novel, investigational, preferential, oral PDE4B inhibitor BI 015550 [1] in a phase 2 study (NCT04419506), either in the presence or absence of background anti-fibrotics. The findings were simultaneously published in the New England Journal of Medicine [2]. IPF is...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on